Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Small Cell Lung Carcinoma 1Refractory or Relapsed Solid Tumors 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Lethal Congenital Contracture Syndrome 2 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Barrett Esophagus 1Advanced Breast Cancer 1Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 8Fluorouracil 8Nivolumab 7Leucovorin 7Paclitaxel 6Capecitabine 5Taxes 4Specimen Handling 4pembrolizumab 3Trastuzumab 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Cisplatin 3zimberelimab 2zanidatamab 2Radiotherapy 2Folfox protocol 2Carboplatin 2zolbetuximab 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1tislelizumab 1quemliclustat 1obeticholic acid 1futibatinib 1dehydroftorafur 1cixutumumab 1balstilimab 1Saline Solution 1Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Itraconazole × 30 days × Clear all
NCT06732388 2026-05-13

Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus

National Cancer Institute (NCI)

Phase 2 Not yet recruiting
64 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Barrett Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡